StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)

Close on Nov 17, 2026Market cap $122.22MP/E –Yield –

Fate Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

No gross margin figures for Fate Therapeutics

Fate Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Fate Therapeutics figures

See a number that looks wrong?